Sirtex Medical gets unsolicited $1.41B counteroffer from Chinese investment firm

stock market prices
Australian biotech Sirtex Medical received an unsolicited $1.41 billion counteroffer from Chinese fund manager CDH Investments. (Ahmad Ardity)

Sirtex Medical, an Australian biotech, received an unsolicited $1.41 billion counteroffer from Chinese fund manager CDH Investments.

The counteroffer by CDH is a nonbinding, indicative and conditional proposal for 100% of Sirtex stock at $25.28 (AU$33.6) per share.

Sirtex specializes in the treatment of liver cancer with its lead product SIR-Spheres, which are radioactive beads that target high doses of radiation to liver tumors. Sirtex has manufacturing capabilities in the U.S., Singapore and Germany.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Earlier this year, U.S.-based Varian Medical Systems made a surprise $1.3 billion bid for Sirtex that the board of directors continues to support.

The board believes “the existing scheme of arrangement with Varian is in the best interests of Sirtex shareholders and continue to unanimously support and recommend” the Varian offer, the company said in a statement.

RELATED: Varian inks $1.3B takeover of cancer device player Sirtex

Prior to the CDH offer, neither it nor Sirtex were in talks, the company said. The counteroffer was made before a meeting scheduled for Monday to approve the Varian takeover. The Sirtex board said it plans to postpone the Monday meeting to a later date in order to review the CDH offer.

Although the company said it will enter into discussions with CDH, it made clear by highlighting in bold the statement, “There is no certainty that the Indicative Proposal will result in a binding offer and Sirtex recommends that shareholders take no action at this point in time.”

Any acquisition would be conditional upon approval of Australia's Foreign Investment Review Board.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.